In this observational cohort study from the largest multi-institutional databank in Taiwan, we investigated whether combination therapy of SGLT-2 inhibitors and Pio in T2DM patients is associated with an increased risk of bladder cancer. The gene discussed is SLC5A2; the disease is urinary bladder carcinoma.